Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
From 1992 to 2018, liver cancer cases related to hepatitis C fell in Japan.
A recent study tested the effectiveness and tolerability of Technivie (ombitasvir/paritaprevir/ritonavir) among those over 65.
Researchers compared direct-acting-antiviral treatment outcomes between those with and without a history of liver cancer.
These rates are driven in large part by hepatitis B and C.
So far, the Harvoni combo pill had only been approved for use in the United States, the European Union and Canada.
This article which originally appeared in the HCV Advocate, discusses hepatitis C in Japan.
The deaths of three people with hepatitis C taking Olysio has led Japanese health authorities to revise the drugâ€™s packaging to issue a...
BMS has submitted for approval in Japan daclatasvir and asunaprevir as the world’s first interferon- and ribavirin-free hep C treatment.
A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.